TY - JOUR
T1 - Investigational agents against platinum-resistant ovarian cancer
AU - Lorusso, Domenica
AU - Ferrandina, Gabriella
AU - Fanfani, Francesco
AU - Gagliardi, Maria Lucia
AU - Scambia, Giovanni
PY - 2007/3
Y1 - 2007/3
N2 - Ovarian cancer is still the fourth cause of death by cancer among women and is the most fatal among gynaecological tumours. The goal of treatment for patients with recurrent, platinum-resistant (platinum-free interval <6 months) ovarian cancer is the palliation of symptoms because no evidence indicates that present therapies may prolong survival in this setting of patients. Successful management of these patients depends on the identification of agents that are not cross-resistant with platinum compounds. The development of molecular biology is providing us with new information on the molecular basis of cancer, its mechanism of initiation and progression, and supply the need of a more patient-tailored therapy where specific turnours are treated with specific drugs. This paper reports and discusses new developments in the treatment of platinum-resistant ovarian cancer patients. The authors present proteomic advances, including the HER kinases, the 26S proteasome and the angiogenesis pathway. The opportunities to change the treatment of ovarian cancer will require creative clinical trial design but the next 10 years promise to be filled with therapeutic advances for patients with ovarian cancer.
AB - Ovarian cancer is still the fourth cause of death by cancer among women and is the most fatal among gynaecological tumours. The goal of treatment for patients with recurrent, platinum-resistant (platinum-free interval <6 months) ovarian cancer is the palliation of symptoms because no evidence indicates that present therapies may prolong survival in this setting of patients. Successful management of these patients depends on the identification of agents that are not cross-resistant with platinum compounds. The development of molecular biology is providing us with new information on the molecular basis of cancer, its mechanism of initiation and progression, and supply the need of a more patient-tailored therapy where specific turnours are treated with specific drugs. This paper reports and discusses new developments in the treatment of platinum-resistant ovarian cancer patients. The authors present proteomic advances, including the HER kinases, the 26S proteasome and the angiogenesis pathway. The opportunities to change the treatment of ovarian cancer will require creative clinical trial design but the next 10 years promise to be filled with therapeutic advances for patients with ovarian cancer.
KW - Antiangiogenetic agents
KW - Molecular biology
KW - Ovarian cancer
KW - Platinum resistance
UR - http://www.scopus.com/inward/record.url?scp=33947183813&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33947183813&partnerID=8YFLogxK
U2 - 10.1517/13543784.16.3.325
DO - 10.1517/13543784.16.3.325
M3 - Article
C2 - 17302527
AN - SCOPUS:33947183813
VL - 16
SP - 325
EP - 336
JO - Expert Opinion on Investigational Drugs
JF - Expert Opinion on Investigational Drugs
SN - 1354-3784
IS - 3
ER -